Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses some of the key topics of interest in the field of myeloproliferative neoplasms (MPNs) currently. In essential thrombocythemia (ET) and polycythemia vera (PV), this includes finding an agent to modify the disease course and prevent progression to myelofibrosis (MF) and leukemia, as well as determining how to best combine agents, and the upcoming approval of ropeginterferon alfa-2b. In MF, this includes investigating how to best sequence available agents, manage cytopenic MF and stop progression in patients with blastic transformation. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.